Clinical Trial Update: Long Term Safety Study of NVA237 vs QAB149 in COPD Patients [Phase 3]

View source ↗

Summary

Phase 3 long-term safety trial comparing NVA237 with QAB149 in COPD patients has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237
• QAB149

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2016-03-16